Quantcast

Latest Metformin Stories

2011-06-27 14:14:13

New data presented at the American Diabetes Association 71st Scientific Sessions In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET® (sitagliptin/metformin HCl) tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy....

2011-06-27 05:00:00

THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company presented clinical data from a mechanistic study of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2 diabetes at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California....

2011-06-25 07:30:00

SAN DIEGO, June 25, 2011 /PRNewswire/ -- Novo Nordisk will present data from two extension studies at the 71st Annual Scientific Sessions of the American Diabetes Association (ADA) which show that Victoza® (liraglutide [rDNA origin] injection), taken once-daily, in combination with metformin and/or sulfonylurea, helped patients achieve blood sugar control after switching from other commonly used type 2 diabetes therapies. Although not a weight loss product, the data also...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announce results presented at a late-breaking poster session demonstrating linagliptin was as effective at lowering blood sugar as glimepiride, and with weight loss instead of weight gain (-1.5 kg with linagliptin versus +1.3 kg with glimepiride), a lower incidence of investigator-defined hypoglycemia (7.5 percent versus 36.1 percent; p<0.0001) and fewer cardiovascular (CV) events...

2011-06-24 16:00:00

SAN DIEGO, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announce Phase III study results for linagliptin, demonstrating improved glycemic control in adults with type 2 diabetes (T2D) whose blood sugar is not adequately controlled. In the open-label arm (n=66) of a 24-week study in adult patients with T2D with a mean baseline hemoglobin A1c (HbA1c or A1C) of 11.8 percent receiving linagliptin 2.5 mg twice daily (bid) plus metformin 1000 mg...

2011-06-24 07:54:00

RIDGEFIELD, Conn. and INDIANAPOLIS, June 24, 2011 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of linagliptin, 5 mg, film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes. If adopted by the European Commission, linagliptin will be the only DPP-4...

2011-06-20 07:00:00

SAN DIEGO and WOODCLIFF LAKE, N.J., June 20, 2011 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that lorcaserin data from the Phase 3 BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus) trial will be presented in poster sessions at the American Diabetes Association's (ADA) 71st Scientific Sessions in San Diego, California. The posters highlighted below will be displayed in the Poster Hall...

2011-06-15 08:00:00

RIDGEFIELD, Conn. and INDIANAPOLIS, June 15, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced Tradjenta(TM) (linagliptin) tablets are now available by prescription in pharmacies across the United States including Walgreens, CVS, Rite Aid and many leading chain and independent pharmacies. The U.S. Food and Drug Administration (FDA) approved TRADJENTA on May 2, 2011 as a prescription medication used along with diet and...

2011-05-27 13:23:13

Scientists from the University of Warwick have discovered why a newly found form of cholesterol seems to be 'ultra-bad', leading to increased risk of heart disease. The discovery could lead to new treatments to prevent heart disease particularly in people with type 2 diabetes and the elderly. The research, funded by the British Heart Foundation (BHF), found that 'ultrabad' cholesterol, called MGmin-low-density lipoprotein (LDL), which is more common in people with type 2 diabetes and the...

08262eb399ee4ca5084c3e3ecfd4f5c0
2011-05-11 11:50:00

Weight-loss groups are describing as "disturbing" a plan to give unborn babies a diet drug to stop them from being born overweight, The Telegraph is reporting. Patients at Liverpool Women's Hospital will be given the drug Metformin to reduce the food supply to their unborn babies. The treatment will not affect the weight of the mothers. Half of the patients in the study will take Metformin pills up to three times a day from 12 weeks gestation, while the other half will be given placebo...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.